Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 5
2020 3
2021 10
2022 11
2023 33
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Tsujino T, et al. Among authors: iwatani k. Cancer Med. 2023 Oct;12(19):19414-19422. doi: 10.1002/cam4.6536. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706578 Free PMC article.
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
Mori K, Yanagisawa T, Fukuokaya W, Iwatani K, Matsukawa A, Katayama S, Pradere B, Laukhtina E, Rajwa P, Moschini M, Albisinni S, Krajewski W, Cimadamore A, Del Giudice F, Teoh J, Urabe F, Kimura S, Murakami M, Tsuzuki S, Miki J, Miki K, Shariat SF, Kimura T; European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Mori K, et al. Among authors: iwatani k. Int J Urol. 2024 Jan;31(1):25-31. doi: 10.1111/iju.15319. Epub 2023 Oct 15. Int J Urol. 2024. PMID: 37840031 Review.
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Bekku K, Laukhtina E, Rajwa P, Quhal F, Pradere B, Fukuokaya W, Iwatani K, Murakami M, Bensalah K, Grünwald V, Schmidinger M, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: iwatani k. Cancer Immunol Immunother. 2024 Jan 30;73(2):38. doi: 10.1007/s00262-023-03621-1. Cancer Immunol Immunother. 2024. PMID: 38289361 Free PMC article. Review.
Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Motlagh RS, Laukhtina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Majdoub M, Pradere B, Abufaraj M, Moschini M, Karakiewicz PI, Iwatani K, Miki J, Kimura T, Shariat SF. Yanagisawa T, et al. Among authors: iwatani k. BJU Int. 2023 Jun;131(6):643-659. doi: 10.1111/bju.15944. Epub 2023 Jan 13. BJU Int. 2023. PMID: 36479820 Review.
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: iwatani k. BJU Int. 2023 Apr;131(4):477-485. doi: 10.1111/bju.15893. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36098556
Prognostic value of PSA bounce after definitive radiotherapy revisited.
Urabe F, Kimura T, Sasaki H, Tashiro K, Iwatani K, Aoki M, Sato S, Takahashi H, Miki K, Egawa S. Urabe F, et al. Among authors: iwatani k. Int J Clin Oncol. 2022 Feb;27(2):411-417. doi: 10.1007/s10147-021-02053-0. Epub 2021 Oct 22. Int J Clin Oncol. 2022. PMID: 34677737
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W, Yanagisawa T, Hashimoto M, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Miki J, Oyama Y, Abe H, Kimura T. Fukuokaya W, et al. Among authors: iwatani k. Cancer Immunol Immunother. 2023 Apr;72(4):841-849. doi: 10.1007/s00262-022-03291-5. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36102985 Free PMC article.
61 results